Ikuti
Keykavous Parang
Keykavous Parang
Professor
Email yang diverifikasi di chapman.edu - Beranda
Judul
Dikutip oleh
Dikutip oleh
Tahun
Self-assembly of peptides to nanostructures
D Mandal, AN Shirazi, K Parang
Organic & biomolecular chemistry 12 (22), 3544-3561, 2014
3112014
Global Cancer Statistics 2022: the trends projection analysis
BS Chhikara, K Parang
Chemical Biology Letters 10 (1), 451-451, 2023
3032023
Mechanism-based design of a protein kinase inhibitor
K Parang, JH Till, AJ Ablooglu, RA Kohanski, SR Hubbard, PA Cole
Nature structural biology 8 (1), 37-41, 2001
2872001
A global review on short peptides: frontiers and perspectives
V Apostolopoulos, J Bojarska, TT Chai, S Elnagdy, K Kaczmarek, ...
Molecules 26 (2), 430, 2021
2532021
Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity
BJ Fowler, BD Gelfand, Y Kim, N Kerur, V Tarallo, Y Hirano, S Amarnath, ...
Science 346 (6212), 1000-1003, 2014
2322014
Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event
R Bhandari, A Saiardi, Y Ahmadibeni, AM Snowman, AC Resnick, ...
Proceedings of the National Academy of Sciences 104 (39), 15305-15310, 2007
2282007
Cell‐penetrating homochiral cyclic peptides as nuclear‐targeting molecular transporters
D Mandal, A Nasrolahi Shirazi, K Parang
Angewandte Chemie-International Edition 50 (41), 9633, 2011
2152011
Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2'3'-Dideoxythymidine (AZT)
K Parang, LI Wiebe, EE Knaus
Current medicinal chemistry 7 (10), 995-1039, 2000
2042000
Impairment of TrkB-PSD-95 signaling in Angelman syndrome
C Cao, MS Rioult-Pedotti, P Migani, CJ Yu, R Tiwari, K Parang, ...
PLoS biology 11 (2), e1001478, 2013
1802013
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease
T Force, K Kuida, M Namchuk, K Parang, JM Kyriakis
Circulation 109 (10), 1196-1205, 2004
1622004
Current targets for anticancer drug discovery
NH Nam, K Parang
Current drug targets 4 (2), 159-179, 2003
1492003
Designing bisubstrate analog inhibitors for protein kinases
K Parang, PA Cole
Pharmacology & therapeutics 93 (2-3), 145-157, 2002
1472002
Development of cytarabine prodrugs and delivery systems for leukemia treatment
BS Chhikara, K Parang
Expert opinion on drug delivery 7 (12), 1399-1414, 2010
1312010
Design and biological evaluation of cell-penetrating peptide–doxorubicin conjugates as prodrugs
A Nasrolahi Shirazi, R Tiwari, BS Chhikara, D Mandal, K Parang
Molecular pharmaceutics 10 (2), 488-499, 2013
1302013
Synthesis of 3-phenylpyrazolopyrimidine-1, 2, 3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities
A Kumar, I Ahmad, BS Chhikara, R Tiwari, D Mandal, K Parang
Bioorganic & medicinal chemistry letters 21 (5), 1342-1346, 2011
1242011
Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools
SE Park, MI Sajid, K Parang, RK Tiwari
Molecular pharmaceutics 16 (9), 3727-3743, 2019
1212019
Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase
S Lee, X Lin, NH Nam, K Parang, G Sun
Proceedings of the National Academy of Sciences 100 (25), 14707-14712, 2003
1022003
A review (research and patents) on jasmonic acid and its derivatives
A Ghasemi Pirbalouti, SE Sajjadi, K Parang
Archiv der Pharmazie 347 (4), 229-239, 2014
1012014
Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities
BS Chhikara, NS Jean, D Mandal, A Kumar, K Parang
European journal of medicinal chemistry 46 (6), 2037-2042, 2011
1002011
Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate
BS Chhikara, D Mandal, K Parang
Journal of medicinal chemistry 55 (4), 1500-1510, 2012
922012
Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.
Artikel 1–20